SynthesisScientific reports2026
The predictive value of neutrophil-to-lymphocyte ratio for the occurrence, progression, and mortality of diabetic nephropathy: a systematic review and meta-analysis.
Synthesis in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
The neutrophil-to-lymphocyte ratio (NLR) has emerged as a promising inflammatory biomarker in diabetic nephropathy (DN). However, its predictive value across the clinical spectrum of DN, from occurrence to progression and mortality, remains undefined. This study aimed to systematically evaluate the association between NLR and the risk, progression, and mortality of DN through a comprehensive meta-analysis. This systematic review and meta-analysis searched six databases for cohort and case-control studies published up to May 28, 2025. Pooled odds ratios (ORs) and standardized mean differences (SMDs) were calculated. Subgroup and sensitivity analyses explored heterogeneity. This review was prospectively registered in PROSPERO (CRD42024586927). Thirty-nine studies involving 14,300 participants showed that patients with diabetic nephropathy (DN) had higher NLR levels than diabetic controls without nephropathy, demonstrating a significant association between elevated NLR and DN occurrence (SMD = 1.31, 95% CI 0.96–1.66; OR = 2.16, 95% CI 1.85–2.52; both P < 0.00001). Among DN patients, those who experienced kidney function deterioration also exhibited higher NLR values than those with stable kidney function (SMD = 1.02, 95% CI 0.77–1.26, P < 0.00001; OR = 2.12, 95% CI 1.04–4.31, P = 0.04). The association with mortality was marginally non-significant (OR = 1.21, 95% CI 0.99–1.48, P = 0.06). Subgroup analyses showed stronger associations in patients aged ≥ 60 years and those with BMI ≥ 25 kg/m². NLR shows potential as a biomarker for identifying individuals at increased risk of DN occurrence and progression. Given the heterogeneity and possible publication bias among studies, these findings should be interpreted with caution and confirmed by future large-scale, standardized research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.